WinSanTor is a biotechnology brand that focuses on discovering and developing treatments for peripheral neuropathies. With a mission to impact patients' lives, their lead drug, WST-057, is currently undergoing clinical trials to treat diabetic peripheral neuropathy. WinSanTor aims to prevent and reverse nerve damage associated with various types of peripheral neuropathy by repairing and regrowing peripheral nerves.

With a proven management team, world-class advisors, and key opinion leaders, WinSanTor is committed to following the science to accelerate the development of potentially disease-modifying treatments. Through their research and development pipeline, they continuously strive to provide innovative solutions for patients suffering from neuropathy. Whether you suffer from diabetic neuropathy, chemo-induced neuropathy, or HIV neuropathy, WinSanTor invites you to join their clinical trials to find relief and contribute to groundbreaking advancements in neuropathy treatment.

Subscribe to their newsletter for updates and information on clinical trials